

REMARKS

In response to the Restriction Requirement dated June 13, 2007, the applicants hereby elect Group II, namely claims 16-17 and 28-29, drawn to the use of PRL-1 homologous proteins for the manufacture of a medicament for the treatment of obesity, diabetes, and/or metabolic syndrome.

These claims are the European version of a U.S. method of treatment claim such as new claims 38 and 39, and thus the present election is of the method of treating a patient having obesity, diabetes, and/or metabolic syndrome.

Claims 30 – 32 are cancelled without prejudice to the filing of divisional applications directed thereto.


Claims 16-17, 28-29 and new claims 38 and 39 read on the elected invention.

The Examiner also required the election of a single specific PRL-1 homologous protein, and in response to this requirement the applicants elect the molecule of SEQ ID NO: I. All of the elected claims read on this species.

Early and favorable action on the merits it awaited.

Respectfully submitted,

By


Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb